Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)

Trials by Status

completed133%
recruiting133%
withdrawn133%

Recent Activity

1 active trials
Showing 3 of 3
completednot_applicable

Feasibility Study on the FARAVIEW Technology

NCT06175234
withdrawnphase_2

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

NCT04931420
recruitingphase_1

Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

NCT05369065

Clinical Trials (3)

Showing 3 of 3 trials
NCT06175234Not Applicable

Feasibility Study on the FARAVIEW Technology

Completed
NCT04931420Phase 2

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

Withdrawn
NCT05369065Phase 1

Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3